All the news Showing 10 of 448 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir Medicines Patent Pool / 12 November 2018 Inovio and Korean Partner Dose 1st Subject In Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection Inovio press release / 06 September 2018 New hepatitis C drugs mean diseased organs can be used for transplants Philly.com / 15 August 2018 Ascletis Receives NDA Approval from China FDA for Ganovo Ascletis press release / 13 June 2018 China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection Gilead press release / 30 May 2018 Two Hepatitis C Virus Infection Treatments to Be Discontinued MPR / 29 May 2018 NICE nod for Gilead’s pan-genotypic hepatitis C therapy PharmaTimes / 21 February 2018 New three-drug HCV regimen shows nearly 100% response in 6, 8 weeks Healio Hepatology / 30 October 2017 European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 31 July 2017 European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie press release / 31 July 2017 ← Prev12345...45Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive